100 related articles for article (PubMed ID: 22063461)
21. An Update of Neuroendocrine Tumors of the Female Reproductive System.
Kefeli M; Usubütün A
Turk Patoloji Derg; 2015; 31 Suppl 1():128-44. PubMed ID: 26177323
[TBL] [Abstract][Full Text] [Related]
22. Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.
Pezzolo E; Modena Y; Corso B; Giusti P; Gusella M
Eur J Clin Pharmacol; 2015 May; 71(5):529-39. PubMed ID: 25740678
[TBL] [Abstract][Full Text] [Related]
23. Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients.
Soares S; Nogueira A; Coelho A; Assis J; Pereira D; Bravo I; Medeiros R
Int J Biol Markers; 2018 Jan; 33(1):116-123. PubMed ID: 28708208
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
25. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
26. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
29. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Vav3.1 as prognostic marker in endometrial cancer.
Boesch M; Sopper S; Marth C; Fiegl H; Wiedemair A; Rössler J; Hatina J; Wolf D; Reimer D; Zeimet AG
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2067-2076. PubMed ID: 30083818
[TBL] [Abstract][Full Text] [Related]
31. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
32. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
33. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
[TBL] [Abstract][Full Text] [Related]
34. Update on Genetic Testing in Gynecologic Cancer.
Domchek SM; Robson ME
J Clin Oncol; 2019 Sep; 37(27):2501-2509. PubMed ID: 31403865
[No Abstract] [Full Text] [Related]
35. In Silico Study to Predict the Structural and Functional Consequences of SNPs on Biomarkers of Ovarian Cancer (OC) and BPA Exposure-Associated OC.
Zahra A; Hall M; Chatterjee J; Sisu C; Karteris E
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163645
[TBL] [Abstract][Full Text] [Related]
36. A systematic review finds that spin or interpretation bias is abundant in evaluations of ovarian cancer biomarkers.
Ghannad M; Olsen M; Boutron I; Bossuyt PM
J Clin Epidemiol; 2019 Dec; 116():9-17. PubMed ID: 31330251
[TBL] [Abstract][Full Text] [Related]
37. Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.
Green G; Carmona R; Zakeri K; Lee CH; Borgan S; Marhoon Z; Sharabi A; Mell LK
PLoS One; 2016; 11(7):e0156489. PubMed ID: 27383192
[TBL] [Abstract][Full Text] [Related]
38. Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.
Bagnoli M; Shi TY; Gourley C; Speiser P; Reuss A; Nijman HW; Creutzberg CL; Scholl S; Negrouk A; Brady MF; Hasegawa K; Oda K; McNeish IA; Kohn EC; Oza AM; MacKay H; Millan D; Bennett K; Scott C; Mezzanzanica D
Cells; 2019 Feb; 8(3):. PubMed ID: 30813545
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and treatment delay in gynecological malignancies. Does it affect outcome?
Menczer J
Int J Gynecol Cancer; 2000 Mar; 10(2):89-94. PubMed ID: 11240658
[TBL] [Abstract][Full Text] [Related]
40. Defining Prognostic Biomarkers and Optimal Adjuvant Treatment for Gynecologic Cancer.
Beriwal S; Klopp A; Mell L
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):1-4. PubMed ID: 28586944
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
